Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.88)
# 1,550
Out of 5,157 analysts
48
Total ratings
35%
Success rate
3.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $20.06 | +268.89% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $6.38 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $114.37 | -23.06% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $16.38 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $43.52 | - | 1 | Jul 17, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $9.57 | - | 2 | Jun 20, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $10.26 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $27.27 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $19.96 | -34.80% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $4.92 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $51.38 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $95.61 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.65 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.97 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $32.19 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $192.59 | +51.62% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $491.51 | -24.72% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.67 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.02 | - | 1 | May 30, 2017 |
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $20.06
Upside: +268.89%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $6.38
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $114.37
Upside: -23.06%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $16.38
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $43.52
Upside: -
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $9.57
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.26
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $27.27
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $19.96
Upside: -34.80%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.92
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $51.38
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $95.61
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.65
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.97
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.19
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $192.59
Upside: +51.62%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $491.51
Upside: -24.72%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.67
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.02
Upside: -